Purple Biotech Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.3M
- Price
- $1.43
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.82%
- Volume
- 8.5K
About
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
Quick stats
Shares outstanding1.6M
Computed float—
Float / sharesUnknown
Cash runway (months)3.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001614744
Websitehttps://purple-biotech.com
AI Summary
AI-generated1/7
minorbullishoperations update
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
The USPTO has issued a Notice of Allowance for a Purple Biotech patent application covering tri-specific antibody constructs and methods of use, expanding IP protection for the CAPTN-3 platform of conditionally activated multispecific antibodies.
The allowed claims cover dual tumor-associated antigen binders and the platform's modular backbone, which is designed to let the company rapidly generate new antibody candidates by swapping binding domains. Management says the allowance also strengthens future development and partnering potential.
CAPTN-3's lead candidate IM1240 is advancing toward the clinic and IM1305 is in preclinical development, while clinical-stage assets CM24 and NT219 await partnering or investment. The allowance remains subject to payment of issue fees before the patent formally grants.
Red flags
- Notice of Allowance only -- patent not yet issued until required issue fees are paid
- further development of clinical-stage assets CM24 and NT219 is pending partnering or investment, signaling funding dependence